Although older patients (pts) may have less CINV compared with younger ones, preventative treatments with a good safety profile are needed. This analysis evaluates the efficacy and safety of the long-acting neurokinin-1 receptor antagonist (RA) rolapitant according to pt age (
In 3 double-blind studies, pts receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC) were randomized 1:1 to treatment with 180 mg oral rolapitant or placebo prior to chemotherapy, always with a 5-hydroxytryptamine type 3 RA and dexamethasone. Endpoints included complete response (CR; no emesis and no use of rescue medication), no emesis, no nausea (maximum visual analogue scale [VAS]
CR rates, no emesis, and CP were significantly higher with rolapitant (P
Rolapitant provides protection against CINV in elderly pts who were administered emetogenic chemotherapy.
Clinical trial identification
NCT01500226, NCT01499849, NCT01500213
Legal entity responsible for the study
M.S. Aapro: Consultant/Advisor (CA), Research Funding (RF), Speakers Bureau (SB): Helsinn, Hospira, Sandoz, PFM; CA/SB: Teva, Tesaro, Vifor Pharma; CA: Merck; RF: Novartis; SB: Amgen, Novartis, Roche, J&J; Honoraria & Expert Test: Amgen. S. Arora, D. Powers: Employment: Tesaro, Inc.